Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | ELAVL1 | Q15717 | 3/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 9/20 | 0.51 |
| ▸ | HTR6 | P50406 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745818 | 0.90 | KDR (0.51) | KDRELAVL1PTPN11HTR6DRD2 | |
| SCHEMBL13669265 | 0.87 | GAK (0.54) | PTPN11HTR6BRD4 | |
| SCHEMBL13745697 | 0.87 | BRD4 (0.61) | KDRELAVL1PTPN11HTR6DRD2 | |
| SCHEMBL13746471 | 0.86 | PTPN11 (0.43) | KDRELAVL1PTPN11HTR6DRD2 | |
| SCHEMBL15821553 | 0.85 | HTR6 (0.46) | ELAVL1PTPN11HTR6DRD2HTR2A | |
| SCHEMBL2750994 | 0.81 | PDPK1 (0.54) | PTPN11HTR6BRD4 | |
| SCHEMBL1487576 | 0.80 | HTR6 (0.45) | ELAVL1PTPN11HTR6BRD4 | |
| SCHEMBL4169651 | 0.80 | PTPN11 (0.56) | PTPN11BRD4 | |
| SCHEMBL4171120 | 0.79 | PTPN11 (0.75) | PTPN11BRD4 | |
| SCHEMBL4160192 | 0.79 | PTPN11 (0.53) | ELAVL1PTPN11HTR6DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447093-B2 | 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | DYRK1A, DYRK3, DYRK2 | KDR 4793/4885ELAVL1 3944/4885PTPN11 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.